MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ajt.15480

Медицинская библиотека · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

Berger Stefan P, Sommerer Claudia, Witzke Oliver, Tedesco Helio, Chadban Steve, Mulgaonkar Shamkant, Qazi Yasir, de Fijter Johan W, Oppenheimer Federico, Cruzado Josep M, Watarai Yoshihiko, Massari Pablo, Legendre Christophe, Citterio Franco, Henry Mitchell, Srinivas Titte R, Vincenti Flavio, Gutierrez Maria Pilar Hernandez, Marti Ana Maria, Bernhardt Peter, Pascual Julio, TRANSFORM investigators

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant recipients randomized (1:1) within 24 hours of transplantation to receive everolimus (EVR) with reduced-exposure calcineurin inhibitor (EVR + rCNI) or mycophenolate with standard-exposure CNI. Consistent with previously reported 12-month findings, noninferiority of the EVR + rCNI regimen for the primary endpoint of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) <50 mL/min per 1.73 m2 was achieved at month 24 (47.9% vs 43.7%; difference = 4.2%; 95% confidence interval = -0.3, 8.7; P = .006). Mean eGFR was stable up to month 24 (52.6 vs 54.9 mL/min per 1.73 m2 ) in both arms. The incidence of de novo donor-specific antibodies (dnDSA) was lower in the EVR + rCNI arm (12.3% vs 17.6%) among on-treatment patients. Although discontinuation rates due to adverse events were higher with EVR + rCNI (27.2% vs 15.0%), rates of cytomegalovirus (2.8% vs 13.5%) and BK virus (5.8% vs 10.3%) infections were lower. Cytomegalovirus infection rates were significantly lower with EVR + rCNI even in the D+/R- high-risk group (P < .0001). In conclusion, the EVR + rCNI regimen offers comparable efficacy and graft function with low tBPAR and dnDSA rates and significantly lower incidence of viral infections relative to standard-of-care up to 24 months. Clinicaltrials.gov number: NCT01950819.

Для цитирования: Berger Stefan P, Sommerer Claudia, Witzke Oliver, Tedesco Helio, Chadban Steve, Mulgaonkar Shamkant, Qazi Yasir, de Fijter Johan W, Oppenheimer Federico, Cruzado Josep M, Watarai Yoshihiko, Massari Pablo, Legendre Christophe, Citterio Franco, Henry Mitchell, Srinivas Titte R, Vincenti Flavio, Gutierrez Maria Pilar Hernandez, Marti Ana Maria, Bernhardt Peter, Pascual Julio, TRANSFORM investigators. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2019. DOI: 10.1111/ajt.15480.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.